Who Generates Higher Gross Profit? Takeda Pharmaceutical Company Limited or Teva Pharmaceutical Industries Limited

Takeda's Gross Profit Dominance Over Teva: A Decade in Review

__timestampTakeda Pharmaceutical Company LimitedTeva Pharmaceutical Industries Limited
Wednesday, January 1, 2014125683400000011056000000
Thursday, January 1, 2015127197300000011356000000
Friday, January 1, 2016117329600000011859000000
Sunday, January 1, 2017127461000000010825000000
Monday, January 1, 201814375340000008296000000
Tuesday, January 1, 201922014240000007536000000
Wednesday, January 1, 202022035040000007725000000
Friday, January 1, 202124621600000007594000000
Saturday, January 1, 202227834060000006973000000
Sunday, January 1, 202328322570000007646000000
Monday, January 1, 202428322570000008064000000
Loading chart...

In pursuit of knowledge

A Tale of Two Pharmaceutical Giants: Takeda vs. Teva

In the competitive world of pharmaceuticals, gross profit is a key indicator of a company's financial health and market dominance. Over the past decade, Takeda Pharmaceutical Company Limited has consistently outperformed Teva Pharmaceutical Industries Limited in generating gross profit. From 2014 to 2023, Takeda's gross profit surged by approximately 125%, peaking at 2.83 trillion in 2023. In contrast, Teva's gross profit has seen a decline, dropping to around 7.65 billion in 2023, a decrease of nearly 31% from its 2016 peak. This stark contrast highlights Takeda's robust growth strategy and market adaptability, while Teva faces challenges in maintaining its profitability. The data underscores the importance of strategic innovation and market expansion in the pharmaceutical industry, as companies navigate the complexities of global healthcare demands.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025